Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Didanosine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Didanosine | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. * CD4 cell counts of at least 200 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Any evidence of organ dysfunction. * Any clinically significant deviations from spec...
Top 20 of 28 competitors
Didanosine is a small molecule drug being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development and is being developed by Bristol-Myers Squibb Company. The drug is intended for use in patients with HIV, and a clinical trial has been completed to evaluate its effects.
Didanosine is being developed by Bristol-Myers Squibb Company, which is publicly traded under the ticker symbol BMY. The company is conducting clinical research on this small molecule drug for the treatment of HIV Infections, with the drug currently in Phase 1 development.
Didanosine is currently in Phase 1 clinical development. It is an investigational drug for the treatment of HIV Infections and has not yet been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug remains in early-stage clinical development.
Didanosine has one completed clinical trial registered under NCT00002360, titled "A Study Comparing Two Forms of Didanosine in HIV-infected Patients." This Phase 1 trial enrolled 30 participants with HIV Infections and was completed. The trial was uncontrolled and not double-blinded, and it included patients aged 18 years and older.
Didanosine is also known by the brand name Videx, which is a common alternative name for this drug. In clinical research, it is referred to as didanosine, and it is being studied for the treatment of HIV Infections. The drug is in Phase 1 development by Bristol-Myers Squibb.